# pathway_0132

[All questions and paired results](../README.md) · [Method](../METHOD.md) · [Source credits](../THIRD_PARTY_NOTICES.md)

**Task:** `pathway`  
**Author expected answer:** **A** — Antifungal biosynthesis. .

| Reviewer | Expected-answer support | Reasoning / lookup | Validity |
|---|---|---|---|
| GPT-6 Luna | supported | lookup-dependent | valid_review |
| Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | valid_review |

**Paired comparison:** key agree; reasoning agree. Agreement is not proof of correctness. These are separate AI judgments, with no forced consensus or changed key.

## Complete original question

```text
[Protein Sequence]
MYDVIVIGAGWCGLVAAKTYLQVCPDARLLLVDGDSSIGGTWSKERLYPHLVAEAHHGLFEFSDLPMRRDTVLPDGRIPSAAVHDYLTEYATKFDLIDRIRLNTWIENVRREPAVIGDNEAPRWMLTVAGSCEQIPTKKIIIATGLTSEPYMPFLPGRQEFEGEVLHSKALGHPQTGDRISDPSVRHAVVYGGSKSAFDAVYLLLRAGKTVDWVIREQGGGPSMMTPLSILGQPSFRLNNSRLLALFSPHPFDTTVKASWWQRVMHRRSGRLAQLAVIGFWRILAYLLQRPWKYNQSANGRRLRPLLALDSLFWSPATLGVMTHPELWDDIHSGERVTIHRQAITALGKDKRVILDNGVELSADLVVCATGWHARHTLFKPEEQLAVGLPSAVSFDPKSQSEWINLQRKADQEIIEEMPILQKSPVPSVPFRCEDDYHLYRFIAPSREPPSHERSIAYVGFLRTAGAPIVYEAQSLWATAYLTGALDVPGPSERISEVARTNAWIRRRYICGRKVPFALFDFLPYVDMLYRDLGVNPHRKANMVAEICGLYQPRDFQGVVSEWLASRGVKDIENV

[Multiple Choices]
A. Antifungal biosynthesis. .
B. L-methionine biosynthesis via de novo pathway
C. Alkaloid biosynthesis. .
D. L-valine biosynthesis
```

<details>
<summary>Original system instructions, verbatim</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## GPT-6 Luna

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.


**Missing item-specific fact**

> The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.


**Reason**

> Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices.


### Important caveats

- The reviewer-only accession and pathway annotation were not supplied to the evaluated model.
- The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.",
    "reason": "Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study."
  },
  "important_caveats": [
    "The reviewer-only accession and pathway annotation were not supplied to the evaluated model.",
    "The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study.",
    "evidence_ids": ["C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.",
    "missing_item_specific_fact": "The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.",
    "reason": "Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices."
  },
  "important_caveats": [
    "The reviewer-only accession and pathway annotation were not supplied to the evaluated model.",
    "The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation."
  ]
}
```

</details>

## Qwen3.8-Flash-Next-NVFP4

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.


**Missing item-specific fact**

> Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.


**Reason**

> The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation.


### Important caveats

- The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.
- The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.
- The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.
- The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.",
    "reason": "The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.",
    "The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.",
    "The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.",
    "The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational.",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.",
    "missing_item_specific_fact": "Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.",
    "reason": "The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.",
    "The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.",
    "The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.",
    "The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context."
  ]
}
```

</details>

## Existing project source checks of Luna’s review

The notes below were prepared for specific claims in the Luna review. They are not independent validation of Qwen’s claims, expert adjudication, or replacement verdicts.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Reviewer-only source evidence

**Both reviewers received this source evidence separately from the original question. It was not available to the original evaluated model.** Source support and reasoning from the original sequence/choices are distinct assessments.

**Accession:** `A0A0L1JEZ9` (recovered from dataset image-path metadata, not original question text).  
**Sequence applicability:** historical matched; current matched.  
**Historical cutoff:** 2026-05-07; archived entry version 28. Exact author snapshot unknown.

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)  
**Locator:** `/primaryAccession`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-02T04:24:14.766738+00:00.  

```json
"A0A0L1JEZ9"
```

Source SHA-256: `4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9`.

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)  
**Locator:** `/proteinDescription`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-02T04:24:14.766738+00:00.  

```json
{"alternativeNames":[{"fullName":{"evidences":[{"evidenceCode":"ECO:0000303","id":"33857369","source":"PubMed"}],"value":"Restricticin biosynthesis cluster protein 6"}}],"flag":"Precursor","recommendedName":{"ecNumbers":[{"evidences":[{"evidenceCode":"ECO:0000305","id":"33857369","source":"PubMed"}],"value":"1.-.-.-"}],"fullName":{"evidences":[{"evidenceCode":"ECO:0000303","id":"33857369","source":"PubMed"}],"value":"FAD-dependent monooxygenase rstn6"}}}
```

Source SHA-256: `4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9`.

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)  
**Locator:** `/comments/2`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-02T04:24:14.766738+00:00.  

```json
{"commentType":"PATHWAY","texts":[{"evidences":[{"evidenceCode":"ECO:0000269","id":"33857369","source":"PubMed"}],"value":"Antifungal biosynthesis"}]}
```

Source SHA-256: `4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9`.

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)  
**Locator:** `/references/1`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-02T04:24:14.766738+00:00.  

```json
{"citation":{"authors":["Liu N.","Abramyan E.D.","Cheng W.","Perlatti B.","Harvey C.J.B.","Bills G.F.","Tang Y."],"citationCrossReferences":[{"database":"PubMed","id":"33857369"},{"database":"DOI","id":"10.1021/jacs.1c01516"}],"citationType":"journal article","firstPage":"6043","id":"33857369","journal":"J. Am. Chem. Soc.","lastPage":"6047","publicationDate":"2021","title":"Targeted genome mining reveals the biosynthetic gene clusters of natural product CYP51 inhibitors.","volume":"143"},"referenceNumber":2,"referencePositions":["FUNCTION","PATHWAY"]}
```

Source SHA-256: `4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9`.

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)  
**Locator:** `lines 1-16`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 28 / 1.  
**Retrieved:** 2026-11-02T04:24:16.831471+00:00.  

```text
ID   RSTN6_ASPN3             Reviewed;         575 AA.
AC   A0A0L1JEZ9;
DT   05-FEB-2025, integrated into UniProtKB/Swiss-Prot.
DT   11-NOV-2015, sequence version 1.
DT   28-JAN-2026, entry version 28.
DE   RecName: Full=FAD-dependent monooxygenase rstn6 {ECO:0000303|PubMed:33857369};
DE            EC=1.-.-.- {ECO:0000305|PubMed:33857369};
DE   AltName: Full=Restricticin biosynthesis cluster protein 6 {ECO:0000303|PubMed:33857369};
DE   Flags: Precursor;
GN   Name=rstn6 {ECO:0000303|PubMed:33857369}; ORFNames=ANOM_001445;
OS   Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 /
OS   M93).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;
OC   Aspergillus subgen. Circumdati.
OX   NCBI_TaxID=1509407;
```

Source SHA-256: `2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a`.

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)  
**Locator:** `lines 25-32`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 28 / 1.  
**Retrieved:** 2026-11-02T04:24:16.831471+00:00.  

```text
RN   [2]
RP   FUNCTION, AND PATHWAY.
RX   PubMed=33857369; DOI=10.1021/jacs.1c01516;
RA   Liu N., Abramyan E.D., Cheng W., Perlatti B., Harvey C.J.B., Bills G.F.,
RA   Tang Y.;
RT   "Targeted genome mining reveals the biosynthetic gene clusters of natural
RT   product CYP51 inhibitors.";
RL   J. Am. Chem. Soc. 143:6043-6047(2021).
```

Source SHA-256: `2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a`.

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)  
**Locator:** `lines 50-50`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 28 / 1.  
**Retrieved:** 2026-11-02T04:24:16.831471+00:00.  

```text
CC   -!- PATHWAY: Antifungal biosynthesis. {ECO:0000269|PubMed:33857369}.
```

Source SHA-256: `2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a`.

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 132. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). UniProt and Gene Ontology credits are retained in [source notices](../THIRD_PARTY_NOTICES.md).
